BWXT Medical

Product

Last mentioned: Feb 24, 2026

Timeline

  1. Earnings Release

    Both companies report record Q4 results exceeding analyst guidance on revenue and EBITDA.

  2. Debt Refinancing

    BWXT completes $1.25B convertible debt raise to improve capital structure for 2026 expansion.

  3. Fiscal Year End

    BWXT Medical crosses $100M revenue threshold; Kratos hits record $1.57B backlog.

Stories mentioning BWXT Medical 1

pharma Bullish

BWXT Medical Hits $100M Milestone as Radiopharmaceutical Demand Surges

BWXT Technologies reported record Q4 2025 results, highlighted by its medical segment surpassing the $100 million revenue threshold amid a global expansion in nuclear medicine. The company's strategic pivot toward radiopharmaceuticals, supported by a $1.25 billion debt refinancing, positions it as a critical infrastructure provider for the next generation of targeted cancer therapies.

2 sources